The Split Three TKI for AML

The FLIT-3 ITD mutation is a relatively common mutation in the world of AML present in about 30% of the Novo cases. We've just completed a cruel on a international phase three randomized trial, a collaborative trial between the BMT CTN and Estellis. If you're in remission going into transplant and receive a maintenance TKI for split three AML, you can now expect a two year leukemia free survival of above 80%, whereas if you don't receive a maintenance inhibitor after transplantation, your two year leukemiaFree survival is right around 50 to 55%. Now the caveats all that is the majority of those patients did not receive a split three TKI initially as